Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia

Elizabeth A. Griffiths, Steven D. Gore, Craig M. Hooker, Helai P. Mohammad, Michael A. McDevitt, B Douglas Smith, Judith Karp, James G. Herman, Hetty E. Carraway

Research output: Contribution to journalArticle

Abstract

Methylation of tumor suppression genes (TSGs) is common in myeloid malignancies. However, application of this as a molecular marker for risk stratification in patients with AML is limited. To elucidate the impact of patterns of TSG methylation on outcome in cytogenetically normal patients, 106 samples from patients with normal cytogenetic AML were evaluated for methylation of 12 genes by MSP. For sake of comparison, samples from patients with AML and abnormal cytogenetics (n = 63) were also evaluated. Methylation frequencies in the whole group (n = 169) were similar to previous reports for CDH1 (31%), ER (31%), FHIT (9%), p15INK4b (44%), p73 (25%) and SOCS1 (75%). Methylation of CTNNA1 was observed in 10%, CEBP-a in16%, CEBP-d in 2%, MLH1 in 24%, MGMT in 11% and DAPK in 2% of AML samples. We find that DNA methylation was more prevalent in patients with normal compared to karyotypically abnormal AML for most genes; CEBPa (20% vs 9%), CTNNA1 (14% vs 4%) and ER (41% vs 19%) (p <0.05 for all comparisons). In contrast, p73 was more frequently methylated in patients with karyotypic abnormalities (17% vs 38%; p <0.05), perhaps due to specific silencing of the proapoptotic promoter shifting p73 gene expression to the anti-apoptotic transcript. In AML patients with normal cytogenetics, TSG methylation was not associated with event free or overall survival in a multivariate analysis. In patients with AML, TSG methylation is more frequent in patients with normal karyotype than those with karyotypic abnormalities but does not confer independent prognostic information for patients with normal cytogenetics.

Original languageEnglish (US)
Pages (from-to)590-600
Number of pages11
JournalEpigenetics
Volume5
Issue number7
DOIs
StatePublished - Oct 2010

Fingerprint

Acute Myeloid Leukemia
Epigenomics
Methylation
Cytogenetics
Genes
Neoplasms
DNA Methylation
Karyotype
Multivariate Analysis
Gene Expression
Survival

Keywords

  • Cytogenetics
  • DNA methylation
  • Epigenetics
  • Leukemia
  • P73

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Griffiths, E. A., Gore, S. D., Hooker, C. M., Mohammad, H. P., McDevitt, M. A., Smith, B. D., ... Carraway, H. E. (2010). Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics, 5(7), 590-600. https://doi.org/10.4161/epi.5.7.12558

Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. / Griffiths, Elizabeth A.; Gore, Steven D.; Hooker, Craig M.; Mohammad, Helai P.; McDevitt, Michael A.; Smith, B Douglas; Karp, Judith; Herman, James G.; Carraway, Hetty E.

In: Epigenetics, Vol. 5, No. 7, 10.2010, p. 590-600.

Research output: Contribution to journalArticle

Griffiths, EA, Gore, SD, Hooker, CM, Mohammad, HP, McDevitt, MA, Smith, BD, Karp, J, Herman, JG & Carraway, HE 2010, 'Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia', Epigenetics, vol. 5, no. 7, pp. 590-600. https://doi.org/10.4161/epi.5.7.12558
Griffiths, Elizabeth A. ; Gore, Steven D. ; Hooker, Craig M. ; Mohammad, Helai P. ; McDevitt, Michael A. ; Smith, B Douglas ; Karp, Judith ; Herman, James G. ; Carraway, Hetty E. / Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. In: Epigenetics. 2010 ; Vol. 5, No. 7. pp. 590-600.
@article{0a6b7f3fa4f44d1e888629500e2af3ae,
title = "Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia",
abstract = "Methylation of tumor suppression genes (TSGs) is common in myeloid malignancies. However, application of this as a molecular marker for risk stratification in patients with AML is limited. To elucidate the impact of patterns of TSG methylation on outcome in cytogenetically normal patients, 106 samples from patients with normal cytogenetic AML were evaluated for methylation of 12 genes by MSP. For sake of comparison, samples from patients with AML and abnormal cytogenetics (n = 63) were also evaluated. Methylation frequencies in the whole group (n = 169) were similar to previous reports for CDH1 (31{\%}), ER (31{\%}), FHIT (9{\%}), p15INK4b (44{\%}), p73 (25{\%}) and SOCS1 (75{\%}). Methylation of CTNNA1 was observed in 10{\%}, CEBP-a in16{\%}, CEBP-d in 2{\%}, MLH1 in 24{\%}, MGMT in 11{\%} and DAPK in 2{\%} of AML samples. We find that DNA methylation was more prevalent in patients with normal compared to karyotypically abnormal AML for most genes; CEBPa (20{\%} vs 9{\%}), CTNNA1 (14{\%} vs 4{\%}) and ER (41{\%} vs 19{\%}) (p <0.05 for all comparisons). In contrast, p73 was more frequently methylated in patients with karyotypic abnormalities (17{\%} vs 38{\%}; p <0.05), perhaps due to specific silencing of the proapoptotic promoter shifting p73 gene expression to the anti-apoptotic transcript. In AML patients with normal cytogenetics, TSG methylation was not associated with event free or overall survival in a multivariate analysis. In patients with AML, TSG methylation is more frequent in patients with normal karyotype than those with karyotypic abnormalities but does not confer independent prognostic information for patients with normal cytogenetics.",
keywords = "Cytogenetics, DNA methylation, Epigenetics, Leukemia, P73",
author = "Griffiths, {Elizabeth A.} and Gore, {Steven D.} and Hooker, {Craig M.} and Mohammad, {Helai P.} and McDevitt, {Michael A.} and Smith, {B Douglas} and Judith Karp and Herman, {James G.} and Carraway, {Hetty E.}",
year = "2010",
month = "10",
doi = "10.4161/epi.5.7.12558",
language = "English (US)",
volume = "5",
pages = "590--600",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Landes Bioscience",
number = "7",

}

TY - JOUR

T1 - Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia

AU - Griffiths, Elizabeth A.

AU - Gore, Steven D.

AU - Hooker, Craig M.

AU - Mohammad, Helai P.

AU - McDevitt, Michael A.

AU - Smith, B Douglas

AU - Karp, Judith

AU - Herman, James G.

AU - Carraway, Hetty E.

PY - 2010/10

Y1 - 2010/10

N2 - Methylation of tumor suppression genes (TSGs) is common in myeloid malignancies. However, application of this as a molecular marker for risk stratification in patients with AML is limited. To elucidate the impact of patterns of TSG methylation on outcome in cytogenetically normal patients, 106 samples from patients with normal cytogenetic AML were evaluated for methylation of 12 genes by MSP. For sake of comparison, samples from patients with AML and abnormal cytogenetics (n = 63) were also evaluated. Methylation frequencies in the whole group (n = 169) were similar to previous reports for CDH1 (31%), ER (31%), FHIT (9%), p15INK4b (44%), p73 (25%) and SOCS1 (75%). Methylation of CTNNA1 was observed in 10%, CEBP-a in16%, CEBP-d in 2%, MLH1 in 24%, MGMT in 11% and DAPK in 2% of AML samples. We find that DNA methylation was more prevalent in patients with normal compared to karyotypically abnormal AML for most genes; CEBPa (20% vs 9%), CTNNA1 (14% vs 4%) and ER (41% vs 19%) (p <0.05 for all comparisons). In contrast, p73 was more frequently methylated in patients with karyotypic abnormalities (17% vs 38%; p <0.05), perhaps due to specific silencing of the proapoptotic promoter shifting p73 gene expression to the anti-apoptotic transcript. In AML patients with normal cytogenetics, TSG methylation was not associated with event free or overall survival in a multivariate analysis. In patients with AML, TSG methylation is more frequent in patients with normal karyotype than those with karyotypic abnormalities but does not confer independent prognostic information for patients with normal cytogenetics.

AB - Methylation of tumor suppression genes (TSGs) is common in myeloid malignancies. However, application of this as a molecular marker for risk stratification in patients with AML is limited. To elucidate the impact of patterns of TSG methylation on outcome in cytogenetically normal patients, 106 samples from patients with normal cytogenetic AML were evaluated for methylation of 12 genes by MSP. For sake of comparison, samples from patients with AML and abnormal cytogenetics (n = 63) were also evaluated. Methylation frequencies in the whole group (n = 169) were similar to previous reports for CDH1 (31%), ER (31%), FHIT (9%), p15INK4b (44%), p73 (25%) and SOCS1 (75%). Methylation of CTNNA1 was observed in 10%, CEBP-a in16%, CEBP-d in 2%, MLH1 in 24%, MGMT in 11% and DAPK in 2% of AML samples. We find that DNA methylation was more prevalent in patients with normal compared to karyotypically abnormal AML for most genes; CEBPa (20% vs 9%), CTNNA1 (14% vs 4%) and ER (41% vs 19%) (p <0.05 for all comparisons). In contrast, p73 was more frequently methylated in patients with karyotypic abnormalities (17% vs 38%; p <0.05), perhaps due to specific silencing of the proapoptotic promoter shifting p73 gene expression to the anti-apoptotic transcript. In AML patients with normal cytogenetics, TSG methylation was not associated with event free or overall survival in a multivariate analysis. In patients with AML, TSG methylation is more frequent in patients with normal karyotype than those with karyotypic abnormalities but does not confer independent prognostic information for patients with normal cytogenetics.

KW - Cytogenetics

KW - DNA methylation

KW - Epigenetics

KW - Leukemia

KW - P73

UR - http://www.scopus.com/inward/record.url?scp=78449247471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449247471&partnerID=8YFLogxK

U2 - 10.4161/epi.5.7.12558

DO - 10.4161/epi.5.7.12558

M3 - Article

VL - 5

SP - 590

EP - 600

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

IS - 7

ER -